The influence of demographic factors and health-related quality of life on treatment satisfaction in patients with gastroesophageal reflux disease treated with esomeprazole

Van, Degl', Guyatt, Wiklund Ingela, Heels-Ansdell Diane, Armstrong David, Fallone, Tanser Lisa, El-Dika Samer, Chiba Naoki, Barkun, Austin Peggy, Schünemann

Description

The correlation between treatment satisfaction and demographic characteristics, symptoms, or health-related quality of life (HRQL) in patients with gastroesophageal reflux disease (GERD) is unknown. The objective of this study was to assess correlates of treatment satisfaction in patients with GERD receiving a proton pump inhibitor, esomeprazole. Methods Adult GERD patients (n = 217) completed demography, symptom, HRQL, and treatment satisfaction questionnaires at baseline and/or after treatment with esomeprazole 40 mg once daily for 4 weeks. We used multiple linear regressions with treatment satisfaction as the dependent variable and demographic characteristics, baseline symptoms, baseline HRQL, and change scores in HRQL as independent variables. Results Among the demographic variables only Caucasian ethnicity was positively associated with treatment satisfaction. Greater vitality assessed by the Quality of Life in Reflux and Dyspepsia (QOLRAD) and worse heartburn assessed by a four-symptom scale at baseline, were associated with greater treatment satisfaction. The greater the improvement on the QOLRAD vitality (change score), the more likely the patient is to be satisfied with the treatment. Conclusions Ethnicity, baseline vitality, baseline heartburn severity, and change in QOLRAD vitality correlate with treatment satisfaction in patients with GERD.

Sujets

• Demography
• Ésoméprazole
• Gerð

Informations

• Publié par: biomed
• Publié le: 01 janvier 2005
• Nombre de lectures: 10
• Langue: English

Extrait

Health and Quality of Life Outcomes

BioMedCentral

Open Access Research The influence of demographic factors and health-related quality of life on treatment satisfaction in patients with gastroesophageal reflux disease treated with esomeprazole 1 2,3 1 Alessio Degl' Innocenti* , Gordon H Guyatt , Ingela Wiklund , 2 3 4 5 Diane HeelsAnsdell , David Armstrong , Carlo A Fallone , Lisa Tanser , 6 7 3,8 Sander Veldhuyzen van Zanten , Samer ElDika , Naoki Chiba , 4 2 2,7,9 Alan N Barkun , Peggy Austin and Holger J Schünemann

1 2 Address: AstraZeneca R&D, 431 83 Mölndal, Sweden, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, 3 4 Ontario, Canada, Department of Medicine, McMaster University, Hamilton, Ontario, Canada, Division of Gastroenterology, McGill University 5 6 Health Center, Montreal, Quebec, Canada, AstraZeneca, Mississauga, Ontario, Canada, Dalhousie University, Halifax, Nova Scotia, Canada, 7 Department of Medicine, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York, 8 9 USA, Surrey GI Research/Clinic, Guelph, Ontario, Canada and Department of Social & Preventive Medicine, School of Public Health and Health Professions, University at Buffalo, State University of New York, Buffalo, New York, USA Email: Alessio Degl' Innocenti*  [e-mail]; Gordon H Guyatt  [e-mail]; Ingela Wiklund  [e-mail]; Diane HeelsAnsdell  [e-mail]; David Armstrong  [e-mail]; Carlo A Fallone  [e-mail]; Lisa Tanser  [e-mail]; Sander Veldhuyzen van Zanten  [e-mail]; Samer El Dika  [e-mail]; Naoki Chiba  [e-mail]; Alan N Barkun  [e-mail]; Peggy Austin  [e-mail]; Holger J Schünemann  [e-mail] * Corresponding author

Published: 13 January 2005 Received: 14 November 2004 Accepted: 13 January 2005 Health and Quality of Life Outcomes2005,3:4 doi:10.1186/1477-7525-3-4 This article is available from: http://www.hqlo.com/content/3/1/4 © 2005 Degl' Innocenti et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

DemographyesomeprazoleFeeling ThermometerGERDQOLRADtreatment satisfaction

Abstract Background:The correlation between treatment satisfaction and demographic characteristics, symptoms, or health- related quality of life (HRQL) in patients with gastroesophageal reflux disease (GERD) is unknown. The objective of this study was to assess correlates of treatment satisfaction in patients with GERD receiving a proton pump inhibitor, esomeprazole. Methods:Adult GERD patients (n = 217) completed demography, symptom, HRQL, and treatment satisfaction questionnaires at baseline and/or after treatment with esomeprazole 40 mg once daily for 4 weeks. We used multiple linear regressions with treatment satisfaction as the dependent variable and demographic characteristics, baseline symptoms, baseline HRQL, and change scores in HRQL as independent variables. Results:Among the demographic variables only Caucasian ethnicity was positively associated with treatment satisfaction. Greater vitality assessed by the Quality of Life in Reflux and Dyspepsia (QOLRAD) and worse heartburn assessed by a four-symptom scale at baseline, were associated with greater treatment satisfaction. The greater the improvement on the QOLRAD vitality (change score), the more likely the patient is to be satisfied with the treatment. Conclusions:Ethnicity, baseline vitality, baseline heartburn severity, and change in QOLRAD vitality correlate with treatment satisfaction in patients with GERD.

Page 1 of 8 (page number not for citation purposes)